Form PTO-1449	Docket No. GZ 2094.00	Appl. No. 09/812,238
INFORMATION DISCLOSURE STATEMENT	Applicant(s) Charles A. NICOLETTE	
(use several sheets if necessary)	Filing Date: March 19, 2001	Group Art Unit: ~~Not Yet Assigned~~ 1654

U.S. PATENT DOCUMENTS

Examiner Initials	Ref. No.	Date	Document No.	Name	Class	Subclass	Filing Date (if appropriate)

FOREIGN PATENT DOCUMENTS

Examiner Initials	Ref. No.	Date	Document No.	Name	Class	Subclass	Translation YES	Translation NO
ADK	1.	11/02/95	WO 95/29193	Govt. of the United States				

OTHER DOCUMENTS

(including author, title, date, pertinent pages, etc.)

Examiner Initials	Ref. No.	Title
	2.	
	3.	

EXAMINER: ADK	DATE CONSIDERED: 8/19/04

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.

Form PTO-1449	Docket No. 126881209400	Appl. No. 09/812,238
INFORMATION DISCLOSURE STATEMENT	Applicant(s) Charles A. NICOLETTE	
(use several sheets if necessary)	Filing Date: March 19, 2001	Group Art Unit: ~~1614~~ 1654

U.S. PATENT DOCUMENTS

Examiner Initials	Ref. No.	Date	Document No.	Name	Class	Subclass	Filing Date (if appropriate)
ADK	1.	07/28/87	4,683,195	Mullis et al.			
ADK	2.	07/28/87	4,683,202	Mullis			
ADK	3.	06/28/88	4,754,065	Levenson et al.			
ADK	4.	01/24/89	4,800,159	Mullis et al.			
ADK	5.	08/08/95	5,440,013	Kahn			
ADK	6.	11/17/98	5,837,249	Heber-Katz et al.			

FOREIGN PATENT DOCUMENTS

Examiner Initials	Ref. No.	Date	Document No.	Name	Class	Subclass	Translation YES	Translation NO
ADK	7.	08/01/96	WO 96/23060	The Government of the United States of America				

OTHER DOCUMENTS

(including author, title, date, pertinent pages, etc.)

Examiner Initials	Ref. No.	Title
ADK	8.	Altman, J.D. et al., "Phenotypic analysis of antigen-specific T lymphocytes" (1996) *Science* **274(5284)**:94-96
ADK	9.	Bertoni, R. et al., "Human class I supertypes and CTL repertoires extend to chimpanzees" (1998) *J. Immunol.* **161**:4447-4455
ADK	10.	Boczkowski, D. et al., "Dendritic cells pulsed with RNA are potent antigen-presenting cells in vitro and in vivo" (1996) *J. Exp. Med.* **184**:465-472
ADK	11.	Bordignon, C. et al., "Retroviral vector-mediated high-efficiency expression of adenosine deaminase (ADA) in hematopoietic long-term cultures of ADA-deficient marrow cells" (1989) *PNAS USA* **86**:6748-6752
ADK	12.	Carter, B.J., "Adeno-associated virus vectors" (1992) *Curr. Op. Biotechnol.* **3**:533-539
ADK	13.	Caruso, A. et al., "Flow cytometric analysis of activation markers on stimulated T cells and their correlation with cell proliferation" (1997) *Cytometry* **27**:71-76
ADK	14.	Correll, P.H. et al., "Production of human glucocerebrosidase in mice after retroviral gene transfer into multipotential hematopoietic progenitor cells" (1989) *PNAS USA* **86**:8912-8916
ADK	15.	Coulie, P.G., "Human tumour antigens recognized by T cells: new perspectives for anti-cancer vaccines?" (1997) *Molec. Med. Today* **3**:261-268
ADK	16.	Culver, K. et.al., "Lymphocytes as cellular vehicles for gene therapy in mouse and man" (1991) *PNAS USA* **88**:3155-3159
ADK	17.	Dharanipragada, R. et al., "The absolute configuration of an intermediate in the asymmetric synthesis of unusual amino acids" (1992) *Acta. Cryst.* **C48**:1239-1241
ADK	18.	Dharanipragada, R. et al., "Synthetic linear and cyclic glucagon antagonists" (1993) *Int. J. Peptide Protein*

EXAMINER: ADK	DATE CONSIDERED: 8/19/04

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.

Form PTO-1449	Docket No. 126881209400	Appl. No. 09/812,238
INFORMATION DISCLOSURE STATEMENT	Applicant(s) Charles A. NICOLETTE	
(use several sheets if necessary)	Filing Date: March 19, 2001	Group Art Unit: ~~1614~~ 1654

		Res. **42(1)**:68-77
ADK	19.	DiMaio, J. et al., "Synthesis of chiral piperazin-2-ones as model peptidomimetics" (1989) *J. Chem. Soc. Perkin Trans.* **1(9)**:1687-1689
ADK	20.	Feltkamp, M.C.W. et al., "Competition inhibition of cytotoxic T-lymphocyte (CTL) lysis, a more sensitive method to identify candidate CTL epitopes than induction of antibody-detected MHC class I stabilization" (1995) *Immunol. Lett.* **47**:1-8
ADK	21.	Ferguson, et al. "Cell-surface anchoring of proteins via glycosyl-phosphatidylinositol structures" (1988) *Ann. Rev. Biochem.* **57**:285-320
ADK	22.	Fujihashi, K. et al., "Cytokine-specific ELISPOT assay single cell analysis of IL-2, IL-4 and IL-6 producing cells" (1993) *J. Immunol. Meth.* **160**:181-189
ADK	23.	Garvey D.S. et al., "3,4-disubstituted γ-lactam rings as conformationally constrained mimics of peptide derivatives containing aspartic acid or norleucine" (1990) *J. Org. Chem.* **55(3)**:936-940
ADK	24.	Hruby, V.J., "Conformational restrictions of biologically active peptides via amino acid side chain groups" (1982) *Life Sciences* **31**:189-199
ADK	25.	Hruby, V.J. et al. "Emerging approaches in the molecular design of receptor-selective peptide ligands: conformational, topographical and dynamic considerations" (1990) *Biochem J.* **268**:249-262
ADK	26.	Isakov, N. et al., "ZAP-70 binding specificity to T cell receptor tyrosine-based activation motifs: The tandem SH2 domains of ZAP-70 bind distinct tyrosine-based activation motifs with varying affinity" (1995) *J. Exp. Med.* **181**:375-380
ADK	27.	Jones, R.C.F. and G.J. Ward, "Amide bond isosteres: imidazolines in pseudopeptide chemistry" (1988) *Tetrahedron Lett.* **29(31)**3853-3856
ADK	28.	Kahn, M. and S. Bertenshaw, "The incorporation of β-turn prosthetic units into merrifield solid phase peptide synthesis" (1989) *Tetrahedron Lett.* **30(18)**:2317-2320
ADK	29.	Karlsson, S. et al., "Stable gene transfer and tissue-specific expression of a human globin gene using adenoviral vectors" (1986) *The EMBO J.* **5(9)**:2377-2385
ADK	30.	Kawakami, Y. et al., "Cloning of the gene coding for a shared human melanoma antigen recognized by autologous T cells infiltrating into tumor" (1994) *PNAS USA* **91(9)**:3515-3519
ADK	31.	Kazmierski, W. M. and V.J. Hruby, "Asymmetric synthesis of topographically constrained amino acids: synthisis of the optically pure isomers of α,β-dimethyl-phenylalanine and α,β-dimethyl-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid" (1991) *Tetrahedron Lett.* **32(41)**:5769-5772
ADK	32.	Kazmierski, W.M. et al., "Topographic design of peptide neurotransmitters and hormones on stable backbone templates: relation of conformation and dynamics to bioactivity" (1991) *J. Am. Chem. Soc.* **113**:2275-2283
ADK	33.	Kemp, D.S. and P.E. McNamara, "Conformationally restricted cyclic nonapeptides derived from L-cysteine and LL-3-amino-2-piperidone-6-carboxylic acid (LL-Acp), a potent β-turn-inducing dipeptide analogue" (1985) *J. Org. Chem.* **50**:5834-5838
ADK	34.	Kemp, D.S. and B.R. Bowen, "Conformational analysis of peptide-functionalized diacylaminoepindolidiones ^{1}H NMR evidence for β-sheet formation" (1988) *Tetrahedron Lett.* **29(40)**:5081-5082
ADK	35.	Kemp, D.S. and W.E. Stites, "A convenient preparation of derivatives of 3(S)-amino-10(R)-carboxy-1, 6-diaza-cyclodeca-2, 7-dione The dilactam of L-α, γ-diaminobutyric acid and D-glutamic acid: A β-turn template" (1988) *Tetrahedron Lett.* **29(40)**:5057-5060
ADK	36.	Kemp, D.S. and T.P. Curran, "(2, 5S, 8S, 11S)-1-acetyl-1, 4-diaza-3-keto-5-carboxy-10-thia-tricyclo-[2.8.0 ^{4,8}]-ridecane, 1 the preferred conformation of 1 (1=αtemp-OH) and its peptide conjugates αtemp-L-$(Ala)_n$-OR (n=1 to 4) and α-temp –L-Ala-L-Phe-Lys(εBoc)-L-Lys(ε-Boc)-NHMe studies of templates for α-helix

EXAMINER:	DATE CONSIDERED: 8/12/04

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.

Form PTO-1449	Docket No. 126881209400	Appl. No. 09/812,238
INFORMATION DISCLOSURE STATEMENT	Applicant(s) Charles A. NICOLETTE	
(use several sheets if necessary)	Filing Date: March 19, 2001	Group Art Unit: ~~1614~~ 1654

		formation" (1988) *Tetrahedron Lett.* **29(39)**:4935-4938
AK	37.	Kemp, D.S. and J.S. Carter, "Amino acid derivatives that stabilize secondary structures of polypeptides. 4. Practical synthesis of 4-(alkylamino)-3-cyano-6-azabicyclo[3.2.1]oct-3-enes (ben derivatives)as γ-turn templates" (1989) *J. Org. Chem.* **54**:109-115
AK	38.	McGrory, W.J. et al., "Short communications: A simple technique for the rescue of early region I mutation into infectious human adenovirus type 5" (1988) *Virology* **163**:614-617
AK	39.	Merrifield, R.B., "New approaches to the chemical synthesis of peptides" (1967) *Recent Progress in Hormone Res.* **23**:451-482
MK	40.	Miyake, A. et al., "Synthesis and angiotensin converting enzyme inhibitory activity of 1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid derivatives" (1984) *J. Takeda Res. Labs.* **43(3/4)**:53-76 Abstract ONLY
AK	41.	Mosier, D.E. et al., "Resistance to human immunodeficiency virus 1 infection of SCID mice reconstituted with peripheral blood leukocytes from donors vaccinated with vaccinia gp160 and recombinant gp160" (1993) *PNAS. USA* **90**:2443-2447
AK	42.	Muzcyzka, "Use of adeno-associated virus as a general transduction vector for mammalian cells" (1992) *Curr. Top. Microbiol. Immunol.* **158**:97-129
AK	43.	Nagai, U. and K. Sato, "Synthesis of a bicyclic dipeptide with the shape of β-turn central part" (1985) *Tetrahedron Lett.* **26(5)**:647-650
AK	44.	Nair, S.et al., "Soluble proteins delivered to dendritic cells via pH-sensitive liposomes induce primary cytotoxic T lymphocyte responses in vitro" (1992) *J. Exp. Med.* **175**:609-612
AK	45.	Olson, G.L. et al., "Design and synthesis of a protein β-turn mimetic" (1990) *J. Am. Chem. Soc.* **112**:323-333
AK	46.	Paglia, P. et al., "Murine dendritic cells loaded in vitro with soluble protein prime cytotoxic T lymphocytes against tumor antigen in vivo" (1996) *J. Exp. Med.* **183**:317-322
AK	47.	Pardoll, D.M., "Cancer vaccines" (1998) *Nature Med.* **4(5 Suppl.)**:525-531
AK	48.	Parker, et al., "Sequence motifs important for peptide binding to the human MHC class I molecule, HLA-A2" (1992) *J. Immunol.* **149(11)**:3580-3587
AK	49.	Parker, K.C. et al. (1995) "Peptide Birding to MHC Class 1 Molecules: Implications for Antigenic Peptide Prediction" Immunol. Res. 14:34-57.
AK	50.	Parkhurst, M.R. et al., "Improved induction of melanoma-reactive CTL with peptides from the melanoma antigen gp100 modified at HLA-A*0201-binding residues" (1996) *J. Immunol.* **157**:2539-2548
AK	51.	al-Ramadi, B.K. et al., "Lack of strict correlation of functional sensitization with the apparent affinity of MHC/peptide complexes for the TCR" (1992) *J. Immunol.* **155(2)**:662-673
AK	52.	Rill, D.R. et al., "An approach for the analysis of relapse and marrow reconstitution after autologous marrow transplantation using retrovirus-mediated gene transfer" (1992) *Blood* **79(10)**:2694-2700
AK	53.	Rouse, R.J.D. et al., "Induction in vitro of primary cytotoxic T-lymphocyte responses with DNA encoding herpes simplex virus proteins" (1994) *J. Virol.* **68(9)**:5685-5689
AK	54.	Salazar, E. et al., "Agonist peptide from a cytotoxic T-lymphocyte epitope of human carcinoembryonic antigen stimulates production of TC1-type cytokines and increases tyrosine phosphorylation more efficiently than cognate peptide" (2000) *Int. J. Cancer* **85**:829-838
AK	55.	Samanen, J. et al., "5,5-dimethylthiazolidine-4-carboxylic acid (DTC) as a proline analog with restricted conformation" (1990) *Int. J. Peptide Protein Res.* **35**:501-509
AK	56.	Schlesinger, S. and T.W. Dubensky, Jr., "Alphavirus vectors for gene expression and vaccines" (1999) *Curr Opin Biotechnol.* **10(5)**:434-439
AK	57.	Sette, A. et al., "The relationship between class I binding affinity and immunogenicity of potential cytotoxic

EXAMINER:	DATE CONSIDERED: 8/12/04

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.

Form PTO-1449	Docket No. 126881209400	Appl. No. 09/812,238
INFORMATION DISCLOSURE STATEMENT	Applicant(s) Charles A. NICOLETTE	
(use several sheets if necessary)	Filing Date: March 19, 2001	Group Art Unit: ~~1614~~ 1654

		T cell epitopes" (1994) *J. Immunol.* **153(12)**:5586-5592
	58.	Shirai, M. et al., "CTL responses of HLA-A2.1-transgenic mice specific for hepatitis C viral peptides predict epitopes for CTL of humans carrying HLA-A2.1" (1995) *J. Immunol.* **154**:2733-2742
	59.	Stuber, G. et al., "HLA-A0201 and HLA-B7 binding peptides in the EBV-encoded EBNA-1, EBNA-2 and BZLF-1 proteins detected in the MHC class 1 stabilization assay. Low proportion of binding motifs for several HLA class 1 alleles in EBNA-1" (1995) *Int. Immunol.* **7(4)**:653-663
	60.	Tan, L. et al., "An improved assembly assay for peptide binding to HLA-B*2705 and H-2K*class I MHC molecules" (1997) *J. Immunol. Meth.* **209(1)**:25-36
	61.	Tanguay, S. and J.J. Killion, "Direct comparison of ELISPOT and ELISA-based assays for detection of individual cytokine-secreting cells" (1994) *Lymphokine Cytokine Res.* **13(4)**:259-263
	62.	Valmori, D. et al., "Induction of potent antitumor CTL responses by recombinant vaccinia encoding a melan-A peptide analogue" (2000) *J. Immunol.* **164(2)**:1125-1131
	63.	van der Burg, S.H. et al., "Immunogenicity of peptides bound to MHC class I molecules depends on the MHC-peptide complex stability" (1996) *J. Immunol.* **156**:3308-3314
	64.	Ware, C.F. et al., "Recognition of HLA-A2 mutant and variant target cells by an HLA-A2 allospecific human cytotoxic T lymphocyte line" (1983) *J. Immunol.* **131(3)**:1312-1317
	65.	Wilchek, M. and E.A. Bayer, "The avidin-biotin complex in bioanalytical applications" (1988) *Anal. Biochem.* **171**:1-32
	66.	Ying, H. et al., "Cancer therapy using a self-replicating RNA vaccine" (1999) *Nat. Med.* **5(7)**:823-827
	67.	Zabrocki, J.et al., "Conformational mimicry. 1. 1,5-disubstituted tetrazole ring as a surrogate for the cis amide bond" (1988) *J. Am. Chem. Sci.* **110**:5875-5880
	68.	Zechel, C. et al., "Synthetic glucagon antagonists and partial agonists" (1991) *Int. J. Pep. Protein Res.* **38(2)**:131-138
	69.	Zuegel, et al., "Termination of peripheral tolerance to a T cell epitope by heteroclitic antigen analogues" (1998) *J. Immunol.* **161(4)**:1705-1709
	70.	Zweerink, H.J. et al., "Presentation of endogenous peptides to MHC class I-restricted cytotoxic T lymphocytes in transport deletion mutant T2 cells" (1993) *J. Immunol.* **150(5)**:1763-1771

EXAMINER:	DATE CONSIDERED: 8/14/04

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.

PTO/SB/08B (10-01)
Approved for u... ...rough 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B-PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 1 of 1

Complete if Known	
Application Numb r	09/812,238
Filing Dat	March 19, 2001
First Nam d Inv nt r	Charles A. NICOLETTE
Art Unit	~~1614~~ 1654
Examiner Name	Not Yet Assigned
Attorney Docket Number	GZ 2094.00

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher city and/or country where published	T[2]
ADK	1	JUNGBLUTH, A. et al. "Expression of melanocyte-associated markers gp-100 and Melan-A/MART-1 in angiomyolipomas" *Virchows Arch.* (1999) **434**:429-345	
ADK	2	RINGHOFER, M. et al. "Quantitative assessment of the expression of melanoma-associated antigens by non-competitive reverse transcription polymerase chain reaction" *Int'l J. Oncol.* (2001) **19**:983-989	
ADK	3	de VRIES, T.J. et al. "Heterogeneous expression of immunotherapy candidate proteins gp100, MART-1, and tyrosinase in human melanoma cell lines in the human melanocytic lesions" *Cancer Res.* (August 1, 1997) **57**:3223-3229	

~~COPY OF PAPERS ORIGINALLY FILED~~

Examiner's Signature		Date Considered	5/19/04

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1] Applicant's unique citation designation number (optional). [2] Applicant is to place a check mark here if English language Translation is attached.

PTO/SB/08 (2/92)
Sheet 4 of 4

APR 2 2 2002 PATENT & TRADEMARK OFFICE

Form PTO-1449	Docket No. GZ 2094.00	Appl. No. 09/812,238
INFORMATION DISCLOSURE STATEMENT	Applicant(s) Charles A. NICOLETTE	
(use several sheets if necessary)	Filing Date: March 19, 2001	Group Art Unit: ~~1614~~ 1654

U.S. PATENT DOCUMENTS

Examiner Initials	Ref. No.	Date	Document No.	Name	Class	Subclass	Filing Date (if appropriate)

FOREIGN PATENT DOCUMENTS

Examiner Initials	Ref. No.	Date	Document No.	Name	Class	Subclass	Translation YES	Translation NO
ADK	1.	3/20/96	EP 0 702 082 A1	Hagiware, et al.				

OTHER DOCUMENTS

(including author, title, date, pertinent pages, etc.)

Examiner Initials	Ref. No.	Title
ADK	2.	Colona, Marco, et al., (1995) "Cloning of Immunoglobulin-Superfamily Members Associated with HLA-C and HLA-B Recognition by Human Natural Killer Cells" *Science*, **268**:405-408.
ADK	3.	Cockle, S.M., et al., (1989) "Thyrotrophin-releasing hormone-related polypeptides in rabbit prostate and semen are different from those in rabbit hypothalamus" *J. Endocrinology*, **120**: 31-36
		COPY OF PAPERS ORIGINALLY FILED

RECEIVED
APR 25 2002
TECH CENTER 1600/2900

EXAMINER: ADK	DATE CONSIDERED: 8/19/04

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.

PTO/SB/08A (10-01)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form1449A-PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 1 of 1

Complete if Known	
Application Number	09/812,238
Filing Date	March 19, 2001
First Named Inventor	Charles A NICOLETTE
Art Unit	1654 ~~1614~~
Examiner Name	Not Yet Assigned
Attorney Docket Number	GZ 2094.00

OIPE AUG 05 2002 PATENT & TRADEMARK OFFICE

RECEIVED AUG 07 2002 TECH CENTER 1600/2900

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Document Number Number – Kind Code[2] (if known)	Publication Date MM-DD-YY	Name of Patentee or Application of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
ADK	1	US-5,695,937	12/9/97	Kinzler et al.	
ADK	2	US-5,844,075	12/1/98	Kawakami et al.	
ADK	3	US-5,869,445	2/9/99	Cheever, et al.	
ADK	4	US-6,028,059	2/22/00	Curiel, et al.	

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Foreign Patent Document Country Code[3] – Number[4] – Kind Code[5] (if known)	Publication Date MM-DD-YY	Name of Patentee or Application of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T[6]
ADK	5	FR 2,757,169		Institute Nat'l de la Sante et de la Recherche Medical InsermEstabliss Public a Caract Scient et Tech		
ADK	6	WO 97/35035		Genzyme Corp.		
ADK	7	WO 99/02183		CTL Immunotherapies Corp.		
ADK	8	WO 00/20457		Genzyme Corp.		

Examiner's Signature	ADK	Date Considered	8/19/04

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1] Applicant's unique citation designation number (optional). [2] See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. [3] Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4] For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5] Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. [6] Applicant is to place a check mark here if English language Translation is attached.

+ Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to compete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

PTO/SB/08 (2/92)
Sheet 1 of 1

Form PTO-1449	Docket No. GZ 2094.00	Appl. No. 09/812,238
INFORMATION DISCLOSURE STATEMENT	Applicant(s) Charles A. NICOLETTE	
(use several sheets if necessary)	Filing Date: March 19, 2001	Group Art Unit: Not Yet Assigned 1654

U.S. PATENT DOCUMENTS

Examiner Initials	Ref. No.	Date	Document No.	Name	Class	Subclass	Filing Date (if appropriate)

FOREIGN PATENT DOCUMENTS

Examiner Initials	Ref. No.	Date	Document No.	Name	Class	Subclass	Translation YES	Translation NO
AM	1.	~~08/23/95~~	~~0 668 350 A1~~	~~Akzo Nobel N.V.~~				

OTHER DOCUMENTS

(including author, title, date, pertinent pages, etc.)

Examiner Initials	Ref. No.	Title
AM	2.	Parkhurst, M., et al. "Improved induction of melanoma-reactive CTL with peptides from the melanoma antigen gp100 modified at ~~HLA-A*0201-binding residues~~" *The J. Immunology* **157**:2539-2548 (1996).
AM	3.	~~Bakker, A.B. H., et al. "Analogues of CTS epitopes with improved MHC class-I binding capacity elicit anti-~~ melanoma CTL recognizing the wild-type epitope" *Int. J. Cancer* **70**:302-309 (1997).

EXAMINER:	DATE CONSIDERED: 8/19/04

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.

PTO/SB/08B (10-01)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B-PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 1 of 2

Complete if Known	
Application Number	09/812,238
Filing Date	March 19, 2001
First Named Inventor	Charles A. NICOLETTE
Art Unit	~~1614~~ 1654
Examiner Name	Not Yet Assigned
Attorney Docket Number	GZ 2094.00

OIPE AUG 05 2002 PATENT & TRADEMARK OFFICE

RECEIVED AUG 07 2002 TECHNOLOGY CENTER 1600/2900

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher city and/or country where published	T[2]
ADK	1	ALEXANDER-MILLER, M. et al. "Selective expansion of high-or low-avidity cytotoxic T lymphocytes and efficacy for adoptive immunotherapy" *PNAS USA* (1996) **93(9)**:4102-4107	
ADK	2	BLOOM, M.B. et al. "Identification of tyrosine-related protein 2 as a tumor rejection antigen for the B16 melanoma" *J. Exp. Med* (1997). **185(3)**:45	
ADK	3	BORCHARDT, A. et al., "Small molecule-dependent genetic selection in stochastic nanodroplets as a means of detecting protein-ligand interactions on a large scale" *Chem. Biol.* (1997) **4(12)**:961-968	
ADK	4	BOUCHARD, B. et al., "Molecular characterization of a human tyrosinase-related-protein-2 cDNA: Patterns of expression in melanocytic cells" *Eur. J. Biochem* (1994). **219(1-2)**:127-134	
ADK	5	COLACO, C.A.L.S. "Why are dendritic cells central to cancer immunotherapy?" ~~*Mol. Med.*~~ (January 1999) ~~**Today**~~:14-17 Mol Med Today	
ADK	6	FISK, B. et al. "Changes in an HER-2 peptide upregulating HLA-A2 expression affect both conformational epitopes and CTL recognition: Implications for Optimization of antigen presentation and tumor-specific CTL induction" ~~*Immunol.*~~ (1996) **18(4)**:197-209 J. Immunol.	
ADK	7	FORBES, J.F. "The incidence of breast cancer: The global burden, public health considerations" *Seminars in Oncology* (1997) **24(1)**, Suppl. 1. pp. S1-20-S1-35	
ADK	8	GISH, W. and D.J. STATES "Identification of protein coding regions by database similarity search" *Nature Genetics* (1993) **3**:266-273	
ADK	9	GREENLEE, R.T. et al. "Cancer Statistics, 2001" . *CA Cancer J Clin* (2001) **51(1)**:15-36	
ADK	10	KAWAKAMI, Y. et al., "Identification of a human melanoma antigen recognized by tumor-infiltrating lymphocytes associated with *in vivo* tumor rejection" *PNAS USA* (1994) **91**:6458-6462	
ADK	11	KUHNS, J.J. et al. "Poor Binding of a HER-2/neu Eiptope (GP2) to HLA-A2.1 is due to a lack of interactions with the center of the peptide" *J. Biol. Chem.* (1999) **274**:36422-36427	
ADK	12	LINDAUER, M. et al., "The molecular basis of cancer immunotherapy by cytotoxic T lymphocytes" *J. Mol. Med.* (1998) **76**:32-47	
ADK	13	LOCKHART, D.J. and E.A. WINZELER "Genomics, gene expression and DNA arrays" *Nature* (2000) **405**:827-836	
ADK	14	RIES, L.A.G. et al. "The annual report to the nation on the status of cancer, 1973-1997, with a special section on colorectal cancer" *Cancer* (2000) **88(10)**:2398-2424	
ADK	15	RONGEUN, Y, et al. "Identification of new HER2/neu-derived peptide epitopes that can elicit specific CTL against autologous and allogeneic carcinomas and melanomas" *J. Immunol.* (1999) **163**:1037-1044	
ADK	16	ROSENBERG, S.A. et al., "Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma" *Nature Med.* (1998) **4(3)**:321-327	
ADK	17	SALGALLER, M.L. et al., "Recognition of multiple epitopes in the human melanoma antigen gp100 by peripheral blood lymphocytes stimulated *in vitro* with synthetic peptides" *Cancer Res.* (1995) **55**:4972-4979	
ADK	18	SCHENA, M. et al., "Parallel human genome analysis: Microarray-based expression monitoring of 1000 genes" *PNAS USA* (1996) **93**:10614-10619	
ADK	19	SHEPHERD, N.S. et al., "Preparation and screening of an arrayed human genomic library generated with the P1 cloning system" *PNAS USA* (1994) **91**:2629-2633	
ADK	20	SHIKE, M. et al. "Primary prevention of colorectal cancer" *Bulletin of the World Health Organization* (1990) **68(3)**:377-385	
ADK	21	SRINIVAS, P.R. et al. "Proteomics in Early Detection of Cancer" *Clin. Chem.* (2001) **47(10)**:1901-1911	

8/19/04

Sheet 2	of	Attorney Docket Number	2094.00

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher city and/or country where published	T[2]
AJK	22	TAM, J.P. "Synthetic peptide vaccine design: Synthesis and properties of a high-density multiple antigenic peptide system" *PNAS US* (1998)*A* **85**:5409-5413	
AJK	23	TÜRECI, Ö. et al. "Serological analysis of human tumor antigens: Molecular definition and implications" *Mol. Med.* (August 1997) **Today 3(8)**:342-349	
AJK	24	WEI, W-Z. et al. "Protection against mammary tumor growth by vaccination with full-length, modified human ErbB-2 DNA" *Int'l J. Cancer* (1999) **81**:748-754	
AJK	25	ZHAI, Y. et al. "Cloning and characterization of the genes encoding the murine homologues of the human melanoma antigens MART1 and gp100" *J. Immunol* (1997). **20(1)**:15-25	

Examiner's Signature		Date Considered	8/19/04

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1] Applicant's unique citation designation number (optional). [2] Applicant is to place a check mark here if English language Translation is attached.

+ Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to compete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.